A Phase I pharmacokinetic study of JHL1149 in China
Phase of Trial: Phase I
Latest Information Update: 16 Apr 2018
At a glance
- Drugs Bevacizumab (Primary)
- Indications Cancer
- Focus Pharmacokinetics
- 16 Apr 2018 According to a JHL Biotech media release, the China Food and Drug Administration (CFDA) has accepted for review JHL's Clinical Trial Application for a proposed bevacizumab biosimilar, JHL1149, to treat cancer.
- 16 Apr 2018 According to a JHL Biotech media release, the data from this and other trials will support the global registration and commercialization of JHL1149.
- 07 Mar 2018 New trial record